Blue Flower

Dear Madam, Dear Sir,

On behalf of the entire NOXXON team, I am pleased to welcome you to the Investor section of our website. NOXXON is a European biopharmaceutical company developing anti-cancer treatments targeting the tumor microenvironment and is listed on Euronext Growth in Paris.

Our mission and focus is the improvement of cancer therapies and increased survival and quality of life for cancer patients. Our therapies are designed to enhance the efficacy of not only newer immuno-oncology approaches, such as checkpoint inhibitors, but also classical therapies such as chemo- and radiotherapy which remain standard of care for many cancers.

In 2020, we completed a combination trial of NOX-A12 + immunotherapy in colorectal and pancreatic cancers which was conducted at the National Center for Tumor Diseases in Heidelberg, Germany, in collaboration with Merck & Co/MSD. The study confirmed that NOX-A12 is safe and well-tolerated in advanced cancer patients both as a monotherapy and in combination with Keytruda®. Moreover, the encouraging survival data suggest that the combination of NOX-A12 with immunotherapy can impact the biology of the tumor in a clinically relevant manner. After discussions with American and European experts, the company is preparing to start a clinical trial in 2nd line pancreas cancer patients in 2021. The goal of this study will be to determine the most effective chemotherapy combination partner to take NOX-A12 forward into a registrational trial. .

An ongoing trial is testing a different combination strategy: NOX-A12 plus radiotherapy in first-line brain cancer patients for whom there is little to no benefit from the current standard of care chemotherapy. Data from the low dose NOX-A12 cohort showed tumor volume reductions in all patient of between 6 - 60%, with the reduction in one patient scored relative to a second surgical resection. We believe that this is a very promising start to the trial in particular as some of the responses are durable (>16 weeks). We plan to complete this trial in 2021, and to launch an expansion cohort of one of the doses to obtain further data for the potentially registrational Phase 2 we plan to start in 2022.

We are determined to continue working on enhancing the therapeutic impact of anti-cancer therapies by combining them with our compounds NOX-A12 and NOX-E36, and we look forward to keeping you updated as our efforts and activities progress.

Best regards

Aram Mangasarian, PhD
Chief Executive Officer
NOXXON
 

• Download the latest update report on NOXXON by Aurgalys
➥ See all reports on NOXXON here

 

Watch the interview of Aram Mangasarian, CEO of NOXXON Pharma, who presents the glioblastoma trial, NOXXON's clinical approach in this indication and the positive results announced on June 2, 2021
Interview with Aram Mangasarian, CEO of NOXXON, and Direct Dirgeants introducing new supervisory board candidates and goals for NOXXON in 2021 (25 May 2021)
Aram Mangasarian, CEO de Noxxon, LeZoom19H BiotechFinances le 19 05 2020: Nous abordons dans cette conférence les questions d'actualité, leur impact sur l'entreprise et la vision d'Aram sur l'avenir de Noxxon, les relations avec les industriels et les investisseurs.
Aram Mangasarian Pdg Noxxon : "J'espère avoir des nouvelles intéressantes pour les investisseurs cette année". La Web TV à la rencontre des dirigeants au Biomed Event 2020
L’entretien avec Aram Mangasarian, PDG de Noxxon, dans Le journal des biotechs de Boursorama pour brosser les perspectives de la société et de ses deux produits NOX-A12 et NOX-E36.
Le PDG de NOXXON Pharma annonce le transfert de l’action vers le compartiment EURONEXT GROWTH pour être cotée en continu.
NOXXON CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications on BIO-Europe Spring 2017